Immunovaccine begins collaboration to create next-gen biodefense vaccines
The candidates will be assessed as part of a study funded by the U.S. National Institutes of Health that will begin in this quarter of 2012. The study will combine the company's DepoVax adjuvanting technology platform with four vaccine candidates against biological agents that will be developed with a partner.
The candidates will then be tested in a non-human primate challenge model developed by the NIH's National Institute of Allergy and Infectious Diseases.
"This collaboration is consistent with Immunovaccine's strategy for leveraging DepoVax™ to enhance the immunogenicity of even the best vaccine antigen candidates, in as little as a single dose," John Trizzino, Immunovaccine's CEO, said.
The study will assess the potential for the novel vaccine candidates to protect against anthrax and multi-filoviruses such as Marburg. The preliminary research that Immunovaccine conducted showed that an anthrax antigen using the DepoVax-based vaccine increased antibody levels when compared with three doses of an alum-adjuvanted control vaccine. Persistent high antibody levels were induced within four weeks of a single dose of the vaccine.